| Autor: |
Harrison, Stephen A, Rinella, Mary E, Abdelmalek, Manal F, Trotter, James F, Paredes, Angelo H, Arnold, Hays L, Kugelmas, Marcelo, Bashir, Mustafa R, Jaros, Mark J, Ling, Lei, Rossi, Stephen J, DePaoli, Alex M, Loomba, Rohit |
| Zdroj: |
The Lancet; March 2018, Vol. 391 Issue: 10126 p1174-1185, 12p |
| Abstrakt: |
Non-alcoholic steatohepatitis is a chronic liver disease characterised by the presence of hepatic steatosis, inflammation, and hepatocellular injury, for which no Food and Drug Administration (FDA)-approved treatment exists. FGF19 is a hormone that regulates bile acid synthesis and glucose homoeostasis. We aimed to assess the safety and efficacy of NGM282, an engineered FGF19 analogue, for the treatment of non-alcoholic steatohepatitis. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
